Clinical Trial Update: IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma [Phase 1]

View source ↗

Summary

This document reports an update on a Phase 1 trial evaluating the combination of IMP321 with first-line paclitaxel for metastatic breast cancer. The study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IMP321 (eftilagimod alpha)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Immutep S.A.S. | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED